Advertisement
News
Advertisement

Covidien’s Solitaire™ FR Revascularization Device Receives Regulatory Approval in Canada

Thu, 12/13/2012 - 7:00am
The Associated Press

MONTREAL--(BUSINESS WIRE)--Dec 13, 2012--Covidien, a leading global provider of healthcare products, today announced that the Solitaire™ FR Revascularization Device has been approved by Health Canada. The Solitaire FR device is used to restore blood flow to the brain in patients suffering from acute ischemic stroke.

Covidien's Solitaire(TM) FR Revascularization Device has been approved by Health Canada. (Photo: Business Wire) "This new device is taking acute ischemic stroke care to a new level," said Dr. Mayank Goyal, Interventional Neuroradiologist at Foothills Medical Centre in Calgary, Canada, and Principal Investigator of Workflow and Imaging for the SWIFT-Prime (Solitaire FR as Primary Treatment for Acute Ischemic Stroke) study. "It clearly surpasses the first generation of clot-removing procedures, which were only moderately successful in reopening target arteries, and gives us a far superior tool for revascularization in stroke patients.” An acute ischemic stroke can occur when a blood vessel that carries oxygen and nutrients to the brain is blocked by a clot and the flow of blood to the brain is interrupted. According to the Canadian Stroke Network’s Burden of Ischemic Stroke (BURST) study, the healthcare costs for patients in just the first six months after they have a stroke is more than $2.5 billion a year in Canada.

“Stroke is a widespread public health issue, with approximately 50,000 Canadians experiencing a stroke annually,” said Stacy Enxing Seng, President, Vascular Therapies, Covidien. “Solitaire FR is intended to transform the way this potentially fatal and often debilitating condition is treated.” The Solitaire FR device received CE Mark approval in Europe and has been sold in that region by Covidien since November 2009. Solitaire FR is also available in the U.S., where it received U.S. Food and Drug Administration clearance in March 2012.

ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Photos/Multimedia Gallery Available:http://www.businesswire.com/multimedia/home/20121213005241/en/ CONTACT: Vascular Therapies David T. Young, 508-452-1644 Manager, External Communications david.young@covidien.com or Bruce Farmer, 508-452-4372 Vice President Public Relations bruce.farmer@covidien.com or Cole Lannum, CFA, 508-452-4343 Vice President Investor Relations cole.lannum@covidien.com or Todd Carpenter, 508-452-4363 Director Investor Relations todd.carpenter@covidien.com KEYWORD: UNITED STATES NORTH AMERICA CANADA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY MEDICAL DEVICES PHARMACEUTICAL MEDICAL SUPPLIES GENERAL HEALTH SOURCE: Covidien Copyright Business Wire 2012 PUB: 12/13/2012 07:00 /DISC: 12/13/2012 07:00 http://www.businesswire.com/news/home/20121213005241/

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading